CytomX Therapeutics (CTMX) Shares Outstanding (Weighted Average) (2014 - 2026)

CytomX Therapeutics has reported Shares Outstanding (Weighted Average) for 13 years, with the latest figure at $177.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 121.04% year-over-year to $177.3 million; the trailing twelve-month figure through Mar 2026 stood at $177.3 million (up 121.04% YoY), and the FY2024 full-year result was $84.4 million, up 1363.61% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $177.3 million, up from $165.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $177.3 million in Q1 2026, with the low at $5.8 million in Q4 2023.
• Historically, Shares Outstanding (Weighted Average) has averaged $84.2 million across 5 years, with a median of $80.5 million in 2023.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) sank 91.22% — and 2024, when it surged 1363.61%.
• CytomX Therapeutics' Shares Outstanding (Weighted Average) stood at $65.7 million in 2022, then slumped by 91.22% to $5.8 million in 2023, then surged by 1363.61% to $84.4 million in 2024, then jumped by 95.41% to $165.0 million in 2025, then rose by 7.44% to $177.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $177.3 million (Q1 2026), $165.0 million (Q3 2025), and $108.2 million (Q2 2025), per Business Quant data.